No increase in overall rates of opportunistic infections with long-term treatment, following the comparable rates seen in the placebo-controlled period2-4 
Long-term follow-up suggests no increase in the incidence or severity of AEs2,4 
Discontinuation rates due to AEs were low: 1,2 <2% in psoriasis and ≤2.5% in psoriatic arthritis 
No increased risk of clinically meaningful elevations in laboratory parameters compared with placebo5 
Most common AEs were diarrhoea, URTI, nausea, nasopharyngitis and headache in Weeks 0 ≥52ǂ1,3
ǂIncludes all patients who received ≥1 dose of OTEZLA®, regardless of when they were randomised.1,3
†3 years in patients with moderate to severe psoriasis, and 5 years in patients with active PsA.1,2
OTEZLA® (apremilast) is indicated for the treatment of:6
Psoriasis
Psoriatic arthritis
The recommended dose of OTEZLA® is 30 mg taken orally twice daily, approximately 12 hours apart (morning and evening), with no food restrictions. An initial titration schedule is required as shown below in Table 1. No re-titration is required after initial titration.
Table 1. Dose titration schedule6
Patients with renal impairment
No dose adjustment is needed in patients with mild and moderate renal impairment. The dose of apremilast should be reduced to 30 mg once daily in patients with severe renal impairment (creatinine clearance of less than 30 mL per minute estimated by the Cockcroft-Gault equation). For initial dose titration in this group, it is recommended that apremilast be titrated using only the AM schedule listed in Table 1 and the PM doses be skipped.
AE, adverse event; HCP, healthcare professional; MTX, methotrexate; PsA, psoriatic arthritis; URTI, upper respiratory tract infection.
